Is Amgen Really as Cheap as It Looks?

Appearances can be deceiving. You might have run across headlines in recent months about how Amgen (NASDAQ:AMGN) is too cheap of a stock to ignore. I’ve seen several articles that trumpeted the big biotech’s attractive valuation. If you look at Amgen’s forward price-to-earnings (P/E) ratio of 12.4, the stock indeed does appear to be trading…

Is CRISPR Therapeutics a Buy?

With its head start in the emerging gene-editing market, does CRISPR deserve investors’ money more than its rivals do? In the volatile world of biotech, investors can find a number of promising markets that could see significant growth in the years to come. Gene editing is one of these markets that has tremendous potential for…

Where Will Veeva Systems Be in 5 Years?

Digital transformation in life sciences will be a long and steady tailwind. Shares of life sciences technologist and software provider Veeva Systems (NYSE:VEEV) have been a big winner for the last few years. They’ve gained 400% over the last five-year stretch, and owning them has been one of the best ways to play the pharmaceuticals…

3 Top Small-Cap Stocks to Buy in October

These small-cap healthcare stocks are definitely worth checking out this month. Small-cap stocks can be outstanding growth vehicles for the buy-and-hold crowd. On balance, stocks with market caps below $2 billion have trounced the broader markets over the past two decades. The downside is that small-cap stocks tend to be on the volatile side, and…

Here’s Why Seattle Genetics Climbed 17.6% in September

Data from a pair of clinical trials sent shares of the oncology drugmaker higher. What happened Shares of Seattle Genetics (NASDAQ:SGEN) jumped 17.6% in September, according to data provided by S&P Global Market Intelligence, as the biotech rounded out the month with positive data from a pair of clinical trials presented at the 2019 European Society for…

U.S. IPO Week Ahead: 2 Billion-Dollar Biotechs And A Bank

Two of the largest-ever biotech IPOs by market cap are scheduled for the week ahead. They are joined by an Illinois bank. The three deals plan to raise a combined $550 million. Germany-based BioNTech (NASDAQ:BNTX) is targeting $251 million at a fully diluted market cap of $4.45 billion. That would make it the third-largest development-stage…

What’s Behind PDS Biotech’s Rally?

Shares of the thinly traded, nano-cap biotech PDS Biotechnology Corp (NASDAQ: PDSB) were rallying strongly Thursday on above-average volume.What Happened PDS, which engages in the development of multifunctional immunotherapic products, announced a modified clinical trial collaboration agreement with Merck & Co., Inc. (NYSE: MRK).PDS’ lead Versamune-based immunotherapy PDS0101 will be evaluated in a Phase 2 trial in combination with…